SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WorldFinancial

World Liberty Financial (WLFI) is a focal point of discussion due to a congressional probe into its $500 million investment with an Abu Dhabi entity and its ongoing application for a National Trust Bank Charter. This has sparked intense debate, with some community members forecasting substantial growth from its forthcoming real-world asset platform and app, while others strongly denounce it as a fraudulent scheme.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after its swift decision to cease offering a compounded weight-loss pill following regulatory scrutiny and legal threats from major pharmaceutical companies. The community is divided, with some viewing it as a strategic de-risking move for its core telehealth business, while others criticize it as a major management blunder that damages trust and growth, amidst mixed reactions to its Super Bowl advertisement.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending due to widespread discussions surrounding a potential future merger involving SpaceX and xAI, alongside recent announcements about high-volume Semi production and significant investments in AI, robotics, and autonomous driving. This is fueling bullish outlooks for its long-term vision, though the community also expresses concerns about near-term profitability and ongoing controversies related to its CEO.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as record Super Bowl betting volume is anticipated, with community discussion intensely focused on how burgeoning prediction markets, operating under different regulatory frameworks, will impact its future profitability and market share amidst its own expansion into the evolving sector ahead of its impending earnings report.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid a federal probe into alleged workplace discrimination and high anticipation for a Supreme Court ruling on tariffs that could impact its margins. While some in the community are betting on a strategic turnaround driven by new product innovation and North American growth, others remain skeptical, citing continued weakness in key markets.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following its recent acquisition and new financing designed to strengthen its HAE portfolio, yet community discussion remains largely negative, citing persistent stock undervaluation, increasing short interest, and perceived manipulation, further fueled by public comments from well-known financial personalities.

TOSHI

TOSHI is trending as the crypto community, referencing a broader market recovery and potential "altcoin season," enthusiastically accumulates the "blue cat" meme coin, expecting significant rallies driven by its community-backed status as the "face of Base."

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following a recently announced $250 million financing amendment that extends its capital runway through 2028, fueling community speculation about a potential short squeeze and comparisons to its history of massive parabolic price movements. While many anticipate significant upward momentum, a notable counter-narrative raises concerns about potential dilution from the equity line of credit and the company's underlying profitability.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Community buzz surrounds TG Therapeutics after its Briumvi commercial, featuring Christina Applegate, aired during the Super Bowl, driving significant discussion around increased patient awareness and the drug's "best-in-class" potential for MS.

SPX6900 is an advanced blockchain cryptography token coin capable of limitless possibilities and scientific utilization.

SPX6900

SPX CRYPTO (SPX6900) is trending due to its passionate community's continuous dollar-cost averaging and strong belief in its potential to act as a "meme index" that could "flip the stock market," positioning it as a generational opportunity against traditional finance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape PR Newswire VANCOUVER, BC, Jan. 16, 2026 Issued on behalf...

GT Biopharma Submits IND For GTB-5550 TriKE To Treat Solid Tumors

(RTTNews) - GT Biopharma, Inc. (GTBP) on Thursday said it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for GTB-5550 TriKE, designed to target...

EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment

GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.read more...

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines PR Newswire...

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 PR Newswire VANCOUVER, BC, Dec. 19...

Platform Technologies Drive $211B Surge in Precision Cancer Treatment

Platform Technologies Drive $211B Surge in Precision Cancer Treatment Platform Technologies Drive $211B Surge in Precision Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 11, 2025 Issued on behalf...

Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment

This article is based on TheStreet's Stock & Markets Podcast. Hosted by Chris Versace, the veteran Wall Street investor and lead portfolio manager for TheStreet Pro, the weekly podcasts are available...

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points PR Newswire VANCOUVER, BC, Dec...

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...

Precision Oncology Approaches Drive $312B Market Transformation

Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

GT Biopharma Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

GTBP
GT Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GTBP News

GTBPGT Biopharma Inc